作者：
Mulligan,G. [1]
;
Lichter,D.I. [2]
;
Bacco,A.D. [3]
;
Blakemore,S.J. [4]
;
Berger,A. [5]
;
Koenig,E. [6]
;
Bernard,H. [7]
;
Trepicchio,W. [8]
;
Li,B. [9]
;
Neuwirth,R. [10]
;
Chattopadhyay,N. [11]
;
Bolen,J.B. ;
Dorner,A.J. ;
VanDeVelde,H. ;
Ricci,D. ;
Jagannath,S. ;
Berenson,J.R. ;
Richardson,P.G. ;
Stadtmauer,E.A. ;
Orlowski,R.Z. ;
Lonial,S. ;
Anderson,K.C. ;
Sonneveld,P. ;
Miguel,J.F.S. ;
Esseltine,D.-L. ;
Schu,M.
作者单位：
Takeda Pharmaceuticals International Co., Translational Medicine, 35 Landsdowne St, Cambridge, MA
[1]
Janssen Research and Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium
[2]
University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, United States
[3]
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States
[4]
Clinica Universidad de Navarra, Centro de Investigacíon Medica Aplicada, Pamplona, Spain
[5]
Janssen Research and Development, Raritan, NJ, United States
[6]
Mount Sinai Hospital, New York, NY, United States
[7]
Department of Lymphoma/Myeloma, Division of Cancer Medicine, University of Texas MD Anderson Cancer
[8]
Institute for Myeloma and Bone Cancer Research, West Hollywood, CA, United States
[9]
Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta
[10]
Department of Hematology, Erasmus Medical Centre, University Hospital Rotterdam, Rotterdam
[11]
发布时间
2014-04-03
换一批
